EC330
Based on 9 publication(s) in Google Scholar
EC330 is a leukemia inhibitory factor (LIF) inhibitor. EC330 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
For research use only. We do not sell to patients.
- Purity: 99.90%
- CAS No.: 2016795-77-8
- Formula: C30H32F2O2
- Molecular Weight:462.57
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) EC330
More- Cell Res. 2024 May;34(5):345-354. [Abstract]
- Clin Cancer Res. 2019 Jul 1;25(13):4128-4140. [Abstract]
- Oncogene. 2020 Oct;39(44):6757-6775. [Abstract]
- Neurosci Bull. 2025 Jun;41(6):1003-1020. [Abstract]
- iScience. 2024 Jul 20;27(8):110562. [Abstract]
- Mol Oncol. 2024 Jun;18(6):1665-1686. [Abstract]
- Cancer Med. 2025 Aug;14(15):e71126. [Abstract]
- University of South Dakota. 2026.
- Int J Biol Sci. 2022 Jan 16;18(4):1363-1380. [Abstract]
-
RT-PCR
-
Cell Proliferation/Viability Assay
-
Cell Imaging/Staining
-
In Vivo Efficacy Study
-
WB
Biological Activity
EC330 shows marked specificity in MCF-7 cells overexpressing LIF verses MCF-7 cells. EC330 further shows cytoskeletal disruption and targeting cancer-associated fibroblasts (CAFs) through inhibition of alpha-SMA but not beta-tubulin[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 2016795-77-8
-
Appearance Solid
-
Molecular Weight 462.57
-
Formula C30H32F2O2
-
Color White to gray
-
SMILES
C[C@@]12[C@](O)(C(F)(F)C#C)CC[C@@]1([H])[C@]3([H])CCC4=CC(CCC4=C3[C@@H](C5=CC=C(C6CC6)C=C5)C2)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (9)
-
Journal Impact Factor
-
Most Recent
-
Cell Res
2024 May;34(5):345-354. PMID: 38467743 -
Clin Cancer Res
Leukemia Inhibitory Factor Promotes Castration-resistant Prostate Cancer and Neuroendocrine Differentiation by Activated ZBTB46. [Abstract]2019 Jul 1;25(13):4128-4140. PMID: 30962287
EC330 purchased from MedChemExpress. Usage Cited in: Clin Cancer Res. 2019 Jul 1;25(13):4128-4140. [Abstract]
Proliferation assays in LNCaP, C4–2, PC3, and NCI-H660 cells treated with an LIF inhibitor (EC330) (10, 20, 30, 35, 40, 50, 100 nM) at the indicated concentrations for 24 h
EC330 purchased from MedChemExpress. Usage Cited in: Clin Cancer Res. 2019 Jul 1;25(13):4128-4140. [Abstract]
Colony formation of PC3 and NCI-H660 cells with EC330 (35 nM) treatment for 6 days.
EC330 purchased from MedChemExpress. Usage Cited in: Clin Cancer Res. 2019 Jul 1;25(13):4128-4140. [Abstract]
Tumor growth analysis of NCI-H660 cells subcutaneously inoculated into male nude mice followed by treatment with EC330 (2.5 mg/kg).
EC330 purchased from MedChemExpress. Usage Cited in: Clin Cancer Res. 2019 Jul 1;25(13):4128-4140. [Abstract]
Western blotting for LIFR, p-STAT3, STAT3, CgA, and NSE in PC3 and NCI-H660 cells treated with EC330 (35 nM) for 24 h.
-
Oncogene
EGFR-upregulated LIFR promotes SUCLG2-dependent castration resistance and neuroendocrine differentiation of prostate cancer. [Abstract]2020 Oct;39(44):6757-6775. PMID: 32963351 -
Neurosci Bull
Cancer-Associated Fibroblasts Interact with Schwann Cells for Tumor Perineural Invasion by Oral Squamous Cell Carcinoma. [Abstract]2025 Jun;41(6):1003-1020. PMID: 39998796 -
iScience
WNT1-inducible signaling pathway protein 1 activation through C-X-C motif chemokine ligand 5/C-X-C chemokine receptor type 2/leukemia inhibitory factor/leukemia inhibitory factor receptor signaling promotes immunosuppression and neuroendocrine differentiation in prostate cancer. [Abstract]2024 Jul 20;27(8):110562. PMID: 39175775 -
Mol Oncol
2024 Jun;18(6):1665-1686. PMID: 38381121
EC330 purchased from MedChemExpress. Usage Cited in: Mol Oncol. 2024 Jun;18(6):1665-1686. [Abstract]
Relative mRNA levels of LIF, LIFR, PDL1, neuroendocrine (CHGA, SYP, and ENO2), and stem cell (SOX2 and NANOG) markers in LNCaP cells cultured in CSS‐containing medium for 1 or 3 days, followed by treatment with 35 nM EC330 for 1 day.
-
Cancer Med
CTHRC1 Derived From Cancer-Associated Fibroblasts Promotes Pancreatic Cancer Progression and Metastasis via the LIF-STAT3 Pathway. [Abstract]2025 Aug;14(15):e71126. PMID: 40751418 -
-
Int J Biol Sci
Cancer-associated adipocytes promote the invasion and metastasis in breast cancer through LIF/CXCLs positive feedback loop. [Abstract]2022 Jan 16;18(4):1363-1380. PMID: 35280694
Solvent & Solubility
DMSO : 2.5 mg/mL (5.40 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 0.25 mg/mL (0.54 mM); Clear solution
This protocol yields a clear solution of ≥ 0.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (2.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1618 mL | 10.8092 mL | 21.6183 mL | 54.0459 mL |
| 5 mM | 0.4324 mL | 2.1618 mL | 4.3237 mL | 10.8092 mL |